Acyclic nucleoside phosphonates (ANPs) are nowadays one of the key drugs in the treatment of DNA virus and retrovirus infections. In this work, we report the synthesis and antiviral evaluation of phosphonoamidate and diamidates prodrugs of C5-pyrimidine acyclic nucleosides derivatives functionalized with but-2-enyl-chain. In the phosphonoamidate series, the most active compound 15, showed submicromolar activity against varicella zoster virus (VZV) (EC 50 ¼ 0.09e0.5 mM) and mM activity against human cytomegalovirus (HCMV) and herpes simplex virus (HSV). Separation of single diastereoisomers for compound 14, showed that 14b had better anti-herpesvirus activity and no cytotoxicity compared to the diastereoisomeric mixture 14. Very interestingly, phosphonodiamidate 21 showed anti-herpesvirus activity with excellent activity against wild type and thymidine kinase-deficient (TK À ) VZV strains (EC 50 ¼ 0.47 and 0.2 mM, respectively) and HCMV (EC 50 ¼ 3.5e7.2 mM) without any cytotoxicity (CC 50 > 100).
Introduction
Acyclic nucleoside phosphonates (ANPs), nucleotide analogues with a stable PÀC bond, are the cornerstone of antiviral therapy (De Clercq and Holy, 2005; De Clercq et al., 1987; Pertusati et al., 2012) . Three ANP analogues; cidofovir (1, CDV, Vistide) (De Clercq et al., 1987) adefovir dipivoxil (2, bis-POM PMEA, Hepsera) (Clercq et al., 1986) , tenofovir disoproxil (3, TDF, Viread) (Balzarini et al., 1993) , were the first ANPs approved for the treatment of severe viral infections (Fig. 1 ). More recently, Tenofovir alafenamide (formerly GS-7340), a phosphoroamidate prodrug of Tenofovir, was developed by Gilead Sciences to treat HIV infection and chronic hepatitis B (Callebaut et al., 2015) . In November 2015, the FDA approved its use in the form of tenofovir alafenamide fumarate (4, TAF) for HIV therapy (http://www.gilead.com/news/press-releases/ 2015/11/us-food-and-drug-administration-approves-gileadssingle-tablet-regimen-genvoya-elvitegravir-cobicistatemtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv1-infection).
The activities of ANPs are based on the intracellular phosphorylation by two salvage pathway kinases (nucleoside monophosphate [NMP] and nucleoside diphosphate [NDP] kinases) to their diphosphates (ANP-PPs). ANP-PPs mimic the natural nucleoside triphosphates and are the active form capable of inhibiting the viral DNA polymerases (De Clercq, 2007; Pertusati et al., 2012) .
Since the structure of the ANPs side chain strongly influences their antiviral selectivity, several series of compounds, modified in their acyclic moiety, have been reported. Among them, of particular interest to this project are ANPs analogues with a more rigid acyclic chain. The increased rigidity was achieved by the introduction of a double bond. This structural feature has been found to be important and effective for the antiviral activity of these class of unsaturated ANPs (Stella et al., 2014) .
The introduction of an ethenyl unit into the acyclic side chain allows the ANPs to better mimic the conformation of the ribose ring. In addition, because a double bond has an appreciable electron-withdrawing effect, it maintains an electronic contribution similar to the oxygen atom (Hansch and Leo, 1979) . This last feature assures that the important second dissociation constant of alkenyl-phosphonic acids can closely mirror those of the natural phosphate.
Surprisingly, almost all biologically active ANP are purine derivative. The only pyrimidine based ANP in the market is Cidofovir. In order to identify novel and more potent ANPs, Agrofoglio's group reported the synthesis of several pyrimidine ANPs in which the oxygen heteroatom has been replaced with a double bond having a trans stereochemistry (Oh et al., 2005; Amblard et al., 2005a; Amblard et al., 2005b; Topalis et al., 2011; McGuigan et al., 2013a) . Among the different ANPs synthesised, compounds 5 and 6 proved to be efficient substrates for the human thymidine monophosphate kinase with their bis-POM prodrugs 7 and 8 ( Fig. 1) showing remarkable antiviral activity. Compound 7 for example was particularly active against HSV-1 and HSV-2 (EC 50 ¼ 3.1 and 6.1 mM, respectively) and against TK þ and TK À VZV strains (EC 50 ¼ 0.41 and 0.19 mM, respectively) but not against HCMV (Topalis et al., 2011) . To the best of our knowledge, no other prodrug approach other than bis-POM has been applied to these interesting pyrimidine scaffolds. In search for more potent ANPs, together with a better safety profile, we were interested in study the impact, of the phosphonoamidate and phosphonodiamidate prodrugs on the antiviral activity of ANPs 5 and 6 and compare their antiviral activities with those of the bis-POM derivatives (Topalis et al., 2011) . We were also interested in assessing the antiviral activity of the novel compounds against HSV and VZV TK þ and TK À strains to prove that our prodrugs are able to bypass the first phosphorylation step. The phosphoro(no)amidate approach, proved to be extremely successful both on nucleoside (Sofosbuvir for Hepatitis C https:// www.drugs.com/newdrugs/fda-approves-sovaldi-chronichepatitis-c-3986.html) as well as on acyclic nucleosides with the recent approval of the Tenofovir Alafenamide for the treatment of HIV infection and chronic hepatitis (http://www.gilead.com/news/ press-releases/2016/11/us-food-and-drug-administrationapproves-gileads-vemlidy-tenofovir-alafenamide-for-thetreatment-of-chronic-hepatitis-b-virus-infection). Our group also obtained excellent results using the phosphoroamidate approach on adefovir and tenofovir (Pertusati et al., 2014) as well as on anticancer nucleosides (NUC-1031, completed Phase I/II clinical trial for solid tumours and NUC-3373 among others http://www. nucanabiomed.com/products.html).
Materials and methods

Experimental chemistry
All anhydrous solvents were purchased from SigmaeAldrich, NMR solvents from Cambridge isotope laboratories and reactants from Acros Organics, Sigma Aldrich, Alfa Aesar, Fluka, Carbosynth and Molekula. All reagents commercially available were used without further purification. Analytical Thin Layer Chromatography (TLC): pre-coated aluminium backed plates (60 F254, 0.2 mm thickness, Merck) were visualized under 254 nm UV light or using KMnO4. Preparative TLC was performed with Analtech blanket 2000, 1000 or 500 m silica gel GF. Flash column chromatography was carried out using silica gel supplied by Fisher (60A, 35e70 mm) or with Biotage Isolera One purification system. Analytical High Performance Liquid Chromatography (HPLC) analysis was performed using both Spectra System SCM (with X-select-C18, 5 mm, 2.1.1. General procedure for preparation of phosphoroamidates prodrugs (13e20) phosphonodiamidate (21e23) In a round bottom flask, under an argon atmosphere, the appropriate diester (11 or 12) was dissolved in dry acetonitrile (ACN) and treated with an excess of TMSBr (5 equivalents). The mixture was then stirred overnight at room temperature and then the volatiles evaporated without any contact with air. Then, the flask was charged with the appropriate, dry amino acid ester 4-toluene sulfonate salt (1 equivalents with respect to the 11 or 12), and the solids dissolved in a mixture of dry triethylamine and dry pyridine (1:4 v/v) and heated to 50 C to obtain a homogenous solution. To this, it was added a solution of 2,2-dithiodipyridine (5 equivalents) and triphenylphosphine (5 equivalents) in dry pyridine, prepared in a separate flask, under an argon atmosphere. The resulting mixture was stirred at 50 C for 3e4 h, to reach the complete conversion as monitored by TLC (DCM/MeOH 95:5 v/v). After evaporating all the volatiles, the residue was treated with a mixture of methanol, water, hexane and toluene (1:1:1:1) and transferred into a separatory funnel. The upper layer (Hexane/ toluene) was separated and the aqueous (MeOH/water) extracted 3 times with a mixture of toluene/hexane (1:1). The water/methanol layer was further extracted with DCM (20 mL x 3). The organics were dried over MgSO 4 , filtered and evaporated. The residue was purified with flash column chromatography on silica gel using DCM/MeOH (gradient, usually from 99:1 to 95:5 v/v) as eluting mixture and then by preparative TLC (95:5 v/v) or preparative HPLC (gradient ACN/water 10:90, 100% ACN in 30 min, 100% ACN for 5 min, then ACN/water 10:90 in 2 min).
Biological assays
The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinasedeficient (TK 
Results and discussion
Chemistry
Our research began with the synthesis of the alkenylfunctionalized pyrimidine methyl phosphonates 11 and 12. The general strategy for the convenient stereo-controlled synthesis of these trans-alkene acyclic nucleoside phosphonates from thymine 9 and bromo-uridine 10 (Scheme 1), was based on olefin cross metathesis, developed by Agrofoglio and colleagues (Topalis et al., 2011) . Phosphonic acids 5 and 6 (parent nucleosides) were prepared by treatment of 11 and 12 with an excess of trimethyl bromosilane (TMSBr) followed by aqueous workup (Topalis et al., 2011) (Scheme 1).
The synthesis of phosphonoamidate prodrugs of these new ANPs was then attempted beginning with the phosphonate esters 11 and 12 using the one-pot procedure reported by Holy (Jansa Scheme 1. Synthesis of methyl phosphonates 11 and 12 and the parent phosphonic acids 5a and 6. et al., 2011) and successfully adapted by us for the synthesis of adefovir and tenofovir phosphonoamidate prodrugs (Pertusati et al., 2014) .
Briefly, methylphosphonates 11 and 12 were converted into the correspondent silyl esters by treatment with an excess of trimethylsilyl bromide (Jansa et al., 2011 ). The silyl derivatives were then treated with an excess of phenol (4 equivalents) and L-alanine-Oneopentyl ester (4 equivalents), in presence of a mixture of triphenylphosphine (5 equivalents) and 2,2-dipyridyl disulphide, (Aldrithiol, 5 equivalents). Under this protocol, only traces of the desired phosphonoamidate 14 were detected (TLC, Mass spectra, and 31 P-NMR of the crude mixture) with the phosphonodiamidate 21 being the major product. It is clear from these results that the phenol was not nucleophilic enough to compete with the amino acid ester for the replacement of the silyl ester. Indeed, when the more nucleophilic p-Methoxy phenol was used as aryl alcohol partner in the above reaction sequence, the desired ProTide 13 was obtained in 18% yield although some diamidate was always isolated. Despite the fact that ProTides bearing paraeMethoxy phenol were successfully applied to glucosamine , this aryl moiety might be activated too slowly compared to the unsubstituted aryl prodrugs (Derudas et al., 2009 ). To circumvent this potential problem, we envisaged that increasing the concentration of phenol would allow us to obtain a better yield of the desired ProTide. After several attempts, we found that addition of an excess (6 equivalents) of phenol with respect to the L-alanine neopentyl ester tosilate (1 equivalent) was sufficient to obtain a reasonable yield of phosphonoamidate (Scheme 2 and Table 1 ). However, the phosphonodiamidates were always obtained alongside with the desired products (ProTide: diamidate roughly 1:1, at best). This fact was not completely unwanted since a one-pot reaction gave us two different prodrugs in a fairly reasonable yield. In few cases, with amino acids having bulky esters (L-Ala-O-hexyl, L-valine-O-pentyl ester, L-isoleucine-Opentyl ester), the yields for both products (mono and diamidate) were very low (1e3%) probably due to steric reasons. In some circumstances, it was possible to accomplish the separation by column chromatography on silica gel of the two phosphonoamidate diastereoisomers. This was achieved with compounds 14 and 20 that were isolated as single isomers 14a and 14b and 20a and 20b (Table 1) . Compounds synthesised by this improved procedure are collected in Table 1: When, 5-Bromo uracil derivative 12 was subjected to the reaction conditions of Scheme 2, we were able to isolate a third compound (other than phosphonodiamidate, and ProTide). Analysis by mass spectrometry and 1 H-NMR of this new compound, revealed that the bromine in the nucleobase was replaced with a hydrogen. Indeed, uracil derivative 20 was isolated with a 5% overall yield. We attributed the formation of this derivative to the presence of triphenylphosphine in the reaction medium. Indeed, it has been shown that triphenylphosphine is able to debrominate a-bromocarbonyl compounds (Borowitz and Grossman, 1962; Hoffmann and Diehr, 1962) . To investigate if this was the case, we set up a control experiment consisting in the treatment of a solution of 5-Bromo uracil 24 in a 1:4 mixture of triethylamine and pyridine with triphenylphosphine at 50 C. Indeed, we observed after 3 h, the formation of the corresponding uracil 25 isolated in 50% yield (Scheme 3). The use of TMSBr in the synthetic sequence was considered responsible for the low yield due to the bromination of the alkenyl chain. The low stability of these brominated derivatives, whose formation was observed by mass spectrometry, did not allow their isolation and characterization. The low yield problem was also exacerbated in the case of the 5-bromouracil derivatives. With these substrates, a further reduction in the yield of the desired prodrugs was due to the action of the triphenyl phosphine, which caused the reduction of the C-Br bond in the nucleobase, leading to Table 1 for yields of compounds 13-23.
the formation of the uracil derivatives. The overall result was a lower yield of the desired compounds.
Antiviral evaluation
With our phosphonoamidates 13e20 and bis-amidates 21e23 in hand, we proceeded to investigate their biological activities against a variety of DNA viruses. In particular, we were interested in assessing if our prodrugs were able to perform better than the bis-POM prodrugs 7 and 8 (Agrofoglio and co-workers _ENREF_4 (Topalis et al., 2011) , against HSV-1, Kos strain, HSV-2 (G strain), (TK À ) HSV-1 (Kos acyclovir-resistant strain), VZV wild-type OKA strain, TK À VZV (07/1 strain), HCMV strains AD-169 and Davis, vaccinia virus in HEL cell cultures. As expected from their high polar nature and from literature data 1 , phosphonic acids 5 and 6 resulted totally inactive against all viral strains tested in this study, probably due to their inability to permeate inside the cell.
In the phosphonoamidate family (ProTide), all our prodrugs showed good to moderate activity against both TK þ and TK À VZV strains in HEL cells except for compound 20 (tested both as 1:1 mixture of diastereoisomers and individual isomers, Table 2 , entries 14, 15, 16) which showed no activity against HSV and only a moderate activity against VZV. In this case, the diastereomeric mixture was completely inactive, while one of the two single diastereoisomer 20b, was slightly more active than the other 20a.
Compound 15 (the most active in this phosphonoamidate family) proved to have an inhibitory activity against the different HSV-1, HSV-2, VZV and HCMV strains with activity slightly better that the Bis(POM) prodrug 7 in the case of HSV-2 (EC 50 ¼ 2.9 vs 6.1 mM) and TK À HSV-1 Kos ACV r , (EC 50 ¼ 2.6 vs 9.2 mM). 15 was also less toxic than 7 and 8 and in contrast to the Bis(POM) prodrugs proved active against HCMV. Evaluation of single isomers of 14 showed that the slow eluting isomer (HPLC) 14b, was the most active of the two isomers against HSV, VZV and HCMV (Entry 5 vs. 6) and also the less cytotoxic one (14b EC 50 > 100 vs 14a EC 50 ¼ 19.08). Compound 16 was moderately active against VZV and HSV and inactive against HCMV with a cytotoxicity comparable to 7 (Table 2, Entry 7 vs. 15).
All phosphonoamidate prodrugs having 5-bromouracil as nucleobase were found barely active against HSV, except for 16 that had EC 50 values comparable to that of the BIS(POM) prodrug 7 (Table 2 ; Entries 7e12). Although 16 inhibited VZV replication with EC 50 values in the mM range, it completely lost activity against HCMV.
Compounds 17 to 19 showed anti-HSV and anti-VZV activity like that of the corresponding bis-POM prodrug 8 (Table 2 , Entries 8e11 vs 16) but in contrast to the latter prodrug they also displayed some anti-HCMV activity. No striking anti-vaccinia virus was observed with any of the prodrugs having 5-bromouracil as nucleobase. In case of compound 17, the 1:1 mixture of diastereoisomers showed the same activity as the single isomers 17b.
Based on our experience (McGuigan et al., 2013b) phosphoroand phosphonodiamidates are usually less active than the corresponding ProTide, probably due to a slower processing rates considering that an amino acid ester is less easily displaced than an aryl moiety typical of a ProTide. Quite surprisingly, in our study one out of three phosphonodiamidates (21) ), but was found less active than cidofovir, acyclovir and ganciclovir against wild-type HSV-1 and HSV-2 strains. Finally, the diamidate 21 showed the same antiviral activity against TK þ and TK À VZV strains than the bis-POM prodrug 7 but lower potency against HSV strains (Table 2 , Entries 1 vs Entry 15). Interestingly, its antiviral activity was better than that of the Br-POM prodrug 8 against HSV and VZV except for HSV-1 (Table 2 , Entries 1 vs Entry 16). Importantly, while prodrugs 7 and 8 were unable to inhibit HCMV
replication at the higher concentration tested (40 mM), the EC 50 values for the phosphonodiamidate 21 against HCMV were comparable to those found for the reference anti-HCMV drug ganciclovir. Although prodrugs 7 and 8 were moderately active against Vaccinia virus, our diamidate 13 was inactive. Finally, all our prodrugs were deprived of activity (EC 50 > 100 mM) against the different RNA viruses tested.
Conclusions
In conclusion, we have successfully synthesised a series of phosphonoamidate and diamidates prodrugs of C5-pyrimidine acyclic nucleosides derivatives functionalized with but-2-enylchain. We were able to demonstrate that the phosphonoamidate approach applied to compound 5 and 6 was capable of turning these inactive parent nucleosides to active antiviral agents. In the phosphonoamidate series, the most active compound 15, showed sub-micromolar activity against VZV (EC 50 ¼ 0.09e0.5 mM) and mM activity against HCMV and HSV. Importantly, its activity against both wild type and TK À HSV and VZV strains make it a good candidate for the therapy of acyclovir-resistant viruses due to mutations in the viral thymidine kinase gene. In general, our phosphonoamidates have a comparable, and in some cases, better antiviral activity with respect to the bis-POM derivatives. Very interestingly, our prodrugs were able to inhibit HCMV whereas the bis-POM derivatives 7 and 8 were inactive. Other analogues of these structural motifs with more complex amino acid moieties are under investigation in our laboratory. 8.3 ± 0.9 7.2 ± 0.6 5.8 ± 2.5 0.74 ± 0.32 0.35 ± 0.33 10.1 ± 3.5 5.6 ± 0.5 >100 >100 >100 15 3.8 ± 3.2 2.9 ± 1.6 2.6 ± 2.0 0.50 ± 0.42 0.09 ± 0.05 9.1 ± 1.3 5.6 ± 0.5 !73 ± 39 !100 40 ± 3 16 6.2 ± 3.9 4.4 ± 2.8 4.4 ± 3.4 3.4 ± 3.3 0.8 ± 0.7 >100 >100 >100 !100 24 ± 15 17 47 ± 18 36 ± 3 2 5 ± 13 12.9 ± 7.0 10.2 ± 3.4 76 67 !100 >100 37 ± 19 17b 30 ± 21 36 ± 3 3 0 ± 21 13.4 ± 9.3 9.7 ± 4.5 63 76 !79 ± 30 >100 !86 ± 20 18 35 ± 21 34 ± 0 3 5 ± 21 15.8 ± 1.8 10.2 ± 3.4 49 55 >100 >100 70 ± 27 19 33.5 ± 23.3 10.5 ± 0.7 27.5 ± 24.7 30.7 ± 2.4 9.3 ± 0.5 45 50 >50 >100 68 ± 27 20 >100 >100 >100 >100 100 >100 >100 >100 >100 ND 20a >100 >100 >100 72 40 >100 >100 >100 100 ND 20b >100 >100 >100 39 26 45 41 >100 100 ND 21
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